Glivec (imatinib) CML and GIST Treatment Glivec, CML, and GIST Treatment Information for International Healthcare Professionals Glivec, CML  and GIST Treatment Information for US Residents International Glivec Information from Novartis Oncology Click here to go to Novartis.com Novartis Oncology International Site
International Glivec Information from Novartis Oncology
Ask a question
Haematology and Oncology News from Glivec.com

Our weekly newsletter keeps you informed of the latest haematology and oncology news.

Help us improve Glivec.com.
Please take our short survey.

Print Glivec Information from Novartis Oncology emial
 

Novartis is committed to providing you with the most updated news and information on Glivec® (imatinib), as well as News on the pharmaceutical industry, haematology, and oncology.

Recent Publications

Hassan I, et al.
Surgically Managed Gastrointestinal Stromal Tumors: A Comparative and Prognostic Analysis.
Annals of Surgical Oncollogy (2008 Jan)

Corless CL, Heinrich MC.
Molecular Pathobiology of Gastrointestinal Stromal Sarcomas.
Annual Review Pathology (2007 Oct 16) [Epub ahead of print]

Picard et al.
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Blood (2007 September)

Kantarjian HM et al.
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Cancer (2007 April)

Blay JY et al.
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year:
The French Sarcoma Group-JCO (2007- March)

deLabarthe A et al.
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
Blood (2007 Feb)

Rousselot P et al.
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
Blood (2007 Jan)

Brian J. Druker, M.D. et al.
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
The New England Journal of Medicine (2006 December)

Roy L et al.
Survival advantage from Imatinib compared to the combination Interferon-{alpha} plus Cytarabine in chronic phase CML: historical comparison between two phase 3 trials.
Blood (2006 April)

 

Virtual Exhibit Booth

Week of May 04, 2008
Haematology News
Oncology News

 

Disclaimer: This is an international website for Glivec (imatinib) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the For US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.



Use of this website is subject to our Terms of Use.
© 2008 Novartis Pharma AG